FIELD: medicine.
SUBSTANCE: invention refers to medicine and aims at selecting antiretroviral therapy for co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) taking into account the threat of progressing hepatic fibrosis. Using a set of risk factors of progressive liver fibrosis in patients with HIV/HCV co-infection, liver elastometry parameters and immunological data, the high risk index of a progressive liver fibrosis is calculated by the equation: HRI=4.070+0.099*kPa+0.476*CD4-0.518*IRI, where kPa is the initial elastometry index, CD4 is the CD3+CD4+absolute number of blood cells/ml, the IRI is the immunoregulatory index. At values of HRI≤180 conclude that patient belongs to the risk group of progressive liver fibrosis.
EFFECT: method enables timely selection of therapy.
1 cl, 3 dwg, 3 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF STABLE VIROLOGICAL RESPONSE TO ANTI-VIRAL THERAPY OF CHRONIC VIRAL HEPATITIS C ACCOMPANYING HIV INFECTION | 2013 |
|
RU2558793C2 |
DIAGNOSTIC TECHNIQUE FOR HEPATIC CIRRHOSIS (STAGE F4) IN THE OUTCOME OF CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2724595C1 |
METHOD FOR ASSESSING THE RISK OF PROGRESSION OF LIVER FIBROSIS IN VIRAL HEPATITIS | 2021 |
|
RU2774596C1 |
METHOD FOR PREDICTING THE ABSENCE OF REGRESS OF HEPATIC FIBROSIS IN THE PATIENTS WITH CHRONIC HEPATITIS C | 2019 |
|
RU2723387C1 |
METHOD FOR DIAGNOSING HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C | 2019 |
|
RU2709507C1 |
METHOD OF HEPATIC FIBROSIS ASSESSMENT IN PATIENTS WITH CHRONIC VIRAL HEPATITIS TYPE C | 2009 |
|
RU2416794C1 |
METHOD FOR PREDICTING THE SURVIVAL PERIOD OF PATIENTS WITH THE CLINICAL COURSE OF HIV AND TUBERCULOSIS COINFECTION, ACCOMPANIED BY MULTIDRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | 2021 |
|
RU2764830C1 |
METHOD OF PREDICTING PROGRESSION OF HIV INFECTION IN PATIENTS RECEIVING ANTIRETROVIRAL THERAPY | 2019 |
|
RU2697392C1 |
METHOD OF PREDICTING FAST VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C | 2013 |
|
RU2563812C2 |
METHOD FOR PREDICTION OF LETHAL OUTCOME IN CLINICAL COURSE OF COINFECTION OF HIV AND TUBERCULOSIS, ACCOMPANIED BY MULTIPLE DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS | 2019 |
|
RU2710266C1 |
Authors
Dates
2019-11-08—Published
2018-06-27—Filed